AR078278A1 - ANTAGONISTS OF TIAZOL AND OXAZOL HEPCIDINE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME FOR THE TREATMENT OF ANEMIAS AND ILLNESSES ASSOCIATED WITH IRON DEFICIENCIES. - Google Patents

ANTAGONISTS OF TIAZOL AND OXAZOL HEPCIDINE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME FOR THE TREATMENT OF ANEMIAS AND ILLNESSES ASSOCIATED WITH IRON DEFICIENCIES.

Info

Publication number
AR078278A1
AR078278A1 ARP100103292A ARP100103292A AR078278A1 AR 078278 A1 AR078278 A1 AR 078278A1 AR P100103292 A ARP100103292 A AR P100103292A AR P100103292 A ARP100103292 A AR P100103292A AR 078278 A1 AR078278 A1 AR 078278A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
same
hepcidine
tiazol
anemias
Prior art date
Application number
ARP100103292A
Other languages
Spanish (es)
Inventor
Mark Slack
Peter Otto Geisser
Franz Duerrenberger
Susanna Burckhardt
Stefan Jaeger
Christopher John Yarnold
Wilm Buhr
Felix Funk
Original Assignee
Vifor Int Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vifor Int Ag filed Critical Vifor Int Ag
Publication of AR078278A1 publication Critical patent/AR078278A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Abstract

Reivindicacion 1: Compuestos de la formula general (1), caracterizados porque X está elegido entre S y O, R1 está elegido del grupo que comprende: hidrogeno, amino opcionalmente sustituido, alquilo opcionalmente sustituido, alcoxi opcionalmente sustituido alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, arilo opcionalmente sustituido, heterociclilo opcionalmente sustituido; o R2 y R3 pueden ser iguales o distintos entre sí y representan: hidrogeno, alquilo opcionalmente sustituido, los radicales alquil-, aril- o heterociclilsulfonilo opcionalmente sustituidos alcoxicarbonilo opcionalmente sustituido acilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, arilo opcionalmente sustituido, heterociclilo opcionalmente sustituido; o sus sales farmacéuticamente aceptables.Claim 1: Compounds of the general formula (1), characterized in that X is selected from S and O, R1 is selected from the group comprising: hydrogen, optionally substituted amino, optionally substituted alkyl, optionally substituted alkenyl alkenyl, optionally substituted alkynyl , optionally substituted aryl, optionally substituted heterocyclyl; or R2 and R3 may be the same or different from each other and represent: hydrogen, optionally substituted alkyl, optionally substituted alkyl-, aryl- or heterocyclylsulfonyl radicals optionally substituted alkoxycarbonyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heterocyclyl; or its pharmaceutically acceptable salts.

ARP100103292A 2009-09-09 2010-09-08 ANTAGONISTS OF TIAZOL AND OXAZOL HEPCIDINE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME FOR THE TREATMENT OF ANEMIAS AND ILLNESSES ASSOCIATED WITH IRON DEFICIENCIES. AR078278A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09169861 2009-09-09

Publications (1)

Publication Number Publication Date
AR078278A1 true AR078278A1 (en) 2011-10-26

Family

ID=41582084

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103292A AR078278A1 (en) 2009-09-09 2010-09-08 ANTAGONISTS OF TIAZOL AND OXAZOL HEPCIDINE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME FOR THE TREATMENT OF ANEMIAS AND ILLNESSES ASSOCIATED WITH IRON DEFICIENCIES.

Country Status (3)

Country Link
AR (1) AR078278A1 (en)
TW (1) TW201111379A (en)
WO (1) WO2011029832A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
SG184987A1 (en) 2010-04-22 2012-11-29 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
SI3424534T1 (en) 2014-04-15 2021-08-31 Vertex Pharmaceutical Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
EA039916B1 (en) * 2015-10-23 2022-03-28 Вифор (Интернациональ) Аг Novel ferroportin inhibitors
PE20181496A1 (en) * 2015-10-23 2018-09-18 Vifor Int Ag NOVELTY FERROPORTIN INHIBITORS
AU2017275657B2 (en) 2016-06-02 2021-08-19 Novartis Ag Potassium channel modulators
SI3571193T1 (en) 2017-01-23 2022-04-29 Cadent Therapeutics, Inc. Potassium channel modulators
JOP20180036A1 (en) 2017-04-18 2019-01-30 Vifor Int Ag Novel ferroportin-inhibitor salts
US11286243B2 (en) 2018-12-13 2022-03-29 Global Blood Therapeutics, Inc. Ferroportin inhibitors and methods of use
IL296653A (en) 2020-03-24 2022-11-01 Vifor Int Ag Process for the production of ferroportin inhibitors
TW202304896A (en) 2021-04-22 2023-02-01 瑞士商威佛（國際）股份有限公司 Modified ferroportin inhibitors
WO2023046664A1 (en) 2021-09-21 2023-03-30 Vifor (International) Ag N-substituted ferroportin inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7166448B1 (en) 1999-05-10 2007-01-23 Children's Medical Center Corproation Ferroportin1 nucleic acids and proteins
EP1392345B2 (en) 2001-05-25 2018-02-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
AU2003295644A1 (en) 2002-11-19 2004-07-22 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US7723063B2 (en) 2004-04-28 2010-05-25 Intrinsic Lifesciences Methods for measuring levels of bioactive human hepcidin
JP2008007405A (en) * 2004-12-07 2008-01-17 Takeda Chem Ind Ltd Carboxamide derivative
CA2549477A1 (en) 2005-06-29 2006-12-29 The Regents Of The University Of California Competitive regulation of hepcidin mrna by soluble and cell-associated hemojuvelin
US8629147B2 (en) 2005-11-03 2014-01-14 Chembridge Corporation Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
WO2008036933A2 (en) 2006-09-21 2008-03-27 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the hamp gene
JP2010517529A (en) 2007-02-02 2010-05-27 アムジエン・インコーポレーテツド Hepcidin and hepcidin antibody
AR065628A1 (en) 2007-03-07 2009-06-17 Xenon Pharmaceuticals Inc TRICYCLE COMPOUNDS OF USEFULNESS IN THE TREATMENT OF IRON DISEASE IN THE ORGANISM
AR065785A1 (en) 2007-03-19 2009-07-01 Xenon Pharmaceuticals Inc BIARETO AND BIHETEROARILE COMPOUNDS OF UTILITY IN THE TREATMENT OF IRON DISORDERS
WO2008121861A2 (en) 2007-03-28 2008-10-09 Xenon Pharmaceuticals Inc. Pyrazole and pyrrole compounds useful in treating iron disorders
TWI425945B (en) 2007-05-28 2014-02-11 Seldar Pharma Inc Tetrahydroisoquinolin-1-one derivatives or salt thereof
EP2068855A2 (en) 2007-06-05 2009-06-17 Xenon Pharmaceuticals Inc. Aromatic and heteroaromatic compounds useful in treating iron disorders
GR1006896B (en) 2007-08-24 2010-07-20 Ελληνικο Ινστιτουτο Παστερ, A process for producing a peptide hormone.
ATE553778T1 (en) 2007-10-02 2012-05-15 Inst Nat Sante Rech Med ANTIBODIES SPECIFIC TO HUMAN HEPCIDIN
PE20091261A1 (en) 2007-11-02 2009-08-17 Lilly Co Eli ANTI-HEPCIDIN ANTIBODIES
US20120094974A1 (en) 2008-06-17 2012-04-19 Wei Chen Smoothened receptor modulators

Also Published As

Publication number Publication date
WO2011029832A1 (en) 2011-03-17
TW201111379A (en) 2011-04-01

Similar Documents

Publication Publication Date Title
AR078278A1 (en) ANTAGONISTS OF TIAZOL AND OXAZOL HEPCIDINE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME FOR THE TREATMENT OF ANEMIAS AND ILLNESSES ASSOCIATED WITH IRON DEFICIENCIES.
ECSP19026680A (en) BENZO [b] THIOPHENE COMPOUNDS AS STING AGONISTS
UY33921A (en) N-SUBSTITUTED OXAZINOPTERIDINS AND N-REPLACED OXAZINOPTIRIDINONES
CR20120591A (en) AMINOPIRIMIDINE DERIVATIVES AS MODULATORS OF THE LRRK2
NI201200184A (en) MORPHOLINOPYRIMIDINES AND THEIR USE IN THERAPY
UY31940A (en) SUBSTITUTED DERIVATIVES OF 4,5- (SUBSTITUTED-PIRIDIN-3-IL) -1-METHYL-1H-INDOL, ITS PHARMACEUTICALLY ACCEPTABLE SALTS, POLYMORPHOS, ROTÁMEROS, PRO-DRUGS, ANANTIOMERS, HYDRATES, SOLVATOS OF THE SAME AND COMPOSITIONS
CR9459A (en) BENZODIOXAN AND BENZODIOXOLAN DERIVATIVES AND USES OF THE SAME
UY31254A1 (en) SUBSTITUTED DERIVATIVES OF N4- (5-METHYL-1H-PIRAZOL-3-IL) - 1,3,5-TRIAZINA-2,4-DIAMINE, THEIR ENANTIOMERS, PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME, COMPOSITIONS, PREPARATION PROCESSES AND APPLICATIONS
CL2008003284A1 (en) Compounds derived from 4-benzylamino-1-carboxyacyl-pyridine, cetp inhibitors; pharmaceutical composition comprising them; pharmaceutical combination; and use in the treatment of metabolic, atherosclerosis and cardiovascular diseases, among others.
CL2011000589A1 (en) Compounds derived from pyrrolidin-2-carboxamide, p53-mdm2 interaction inhibitors; pharmaceutical composition that includes them; and its use in the preparation of useful medicines for the treatment of cancer.
ECSP109903A (en) DERIVATIVES OF PIRAZINONA AND ITS USE IN THE TREATMENT OF PULMONARY DISEASES
ECSP10010693A (en) PIRAZOLIC COMPOUNDS 436
SV2010003598A (en) TIAZOL DERIVATIVES USED AS PI 3-CINASA INHIBITORS
UY32203A (en) AMINO PIRIMIDINAS AND ITS USE IN THERAPY
UY31127A1 (en) METABOTROPIC RECEIVER OXYADAZOL LIGANDS FOR GLUTAMATE AND ITS USE AS POTENTIALS - 841
CY1117792T1 (en) COMPETITORS TOY TRPV4
UY35275A (en) AMINOPIRAZINE DERIVATIVES
UY31885A (en) DERIVED FROM THE 1, 3, 5-TRIAZINA-2, 4-DIAMINAS-6-SUBSTITUTED-N-SUBSTITUTED AND PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME, COMPOSITIONS AND APPLICATIONS.
ECSP099216A (en) NEW DERIVATIVES OF DIOSMETINE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CO6351793A2 (en) \ "DERIVATIVES OF INDOL MACROCICLICOS USEFUL AS INHIBITORS OF THE HEPATITIS VIRUS
NI200900183A (en) PYRID [2,3-D] PYRIMIDINE - 7 - ONA COMPOUNDS AS PI3K - ALPHA INHIBITORS FOR THE TREATMENT OF CANCER.
PE20141940A1 (en) TRICYCLIC COMPOUNDS, COMPOSITIONS THAT INCLUDE THEM, AND USES OF THEM
ECSP099506A (en) DERIVATIVES OF 2-QUINOLINONA AND 2 QUINOXALINONA AND ITS USE AS ANTI BACTERIAL AGENTS
UY32316A (en) USEFUL PIPERIDINE DERIVATIVES IN THE TREATMENT OF BACTERIAL INFECTIONS
UY33305A (en) Heterocyclic compounds inhibiting DGAT1

Legal Events

Date Code Title Description
FB Suspension of granting procedure